Despite the above in vitro data supporting that hypomethylating agents up-regulate Treg and suppress conventional CD4+ T cells (117, 118), post-transplantation Aza treatment in patients with high risk of AML and MDS shows no significant differences in terms of overall survival and GVHD incidence in patients compared to the control arm (119). This evidence concerns the gene CD4 and graft versus host disease.